非酒精性脂肪肝无脂肪性肝炎患者显著纤维化的患病率与危险因素
在意大利和芬兰转诊中心1738例肝活检横断面队列中,33.9%(132/389)显著纤维化患者无NASH,10.0%(39/389)无炎症;重度肥胖者NASH与纤维化解离更明显。验证队列47例中34.0%(16/47)基线无NASH。无NASH者中,空腹高血糖、重度脂肪变、轻度炎症或气球样变及PNPLA3 I148M变异与显著纤维化相关。
要点
- 显著纤维化患者中约三分之一无NASH,10.0%无炎症。
- 重度肥胖者NASH与纤维化解离更显著(P < .005)。
- 无NASH者中空腹高血糖、重度脂肪变、PNPLA3 I148M变异与纤维化相关。
核心结论
- 在单时间点肝活检分析中,约三分之一显著纤维化患者无NASH,并在独立队列中验证。
- 无NASH患者中,空腹高血糖、重度脂肪变、轻度炎症或气球样变及PNPLA3 I148M变异可识别显著纤维化风险。
研究设计与样本
- 横断面肝活检队列,纳入意大利和芬兰转诊中心1738例受试者(44.9%为重度肥胖)。
- 验证队列为意大利三级转诊中心118例连续NAFLD患者,接受序贯肝活检。
主要发现
- 横断面队列中,389例显著纤维化患者里132例(33.9%)无NASH,39例(10.0%)无炎症。
- 重度肥胖患者中NASH与纤维化的解离显著大于非重度肥胖者(P < .005)。
- 脂肪变、气球样变和小叶内炎症各自独立与显著纤维化相关(P < .001);年龄、肥胖、空腹高血糖和PNPLA3 I148M变异亦与纤维化相关。
- 无NASH患者中,显著纤维化与脂肪变分级和PNPLA3 I148M变异相关;年龄、空腹高血糖、气球样变和炎症与纤维化相关。
- 验证队列中,47例临床显著纤维化患者中16例(34.0%)基线无NASH;基线无NASH的纤维化患者中,后续活检纤维化进展与空腹高血糖和更严重脂肪变相关(P = .016)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In patients with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) is a risk factor for the development of fibrosis. However, fibrosis has been observed in livers of patients without NASH. We aimed to estimate the prevalence of fibrosis in patients without NASH and risk factors for fibrosis. METHODS: We analyzed data from 1738 subjects (44.9% with severe obesity) in a cross-sectional liver biopsy cohort enrolled at referral centers in Italy and Finland. Biopsy specimens were analyzed histologically by a blinded pathologist at each center, and a diagnosis of NASH was made based on steatosis (≥5% of hepatocytes), hepatocellular ballooning, and lobular inflammation. We also collected data on demographic features, metabolic comorbidities, and genetic factors, and performed logistic regression analyses. Findings were validated using data from 118 consecutive patients with NAFLD who underwent sequential liver biopsies at tertiary referral centers in Italy. RESULTS: In the cross-sectional cohort, 132 of 389 patients (33.9%) with significant fibrosis had no NASH and 39 patients (10.0%) had no inflammation. The dissociation between NASH and fibrosis was significantly greater in patients with severe obesity (P < .005). Steatosis, ballooning, and lobular inflammation each were associated independently with significant fibrosis (P < .001); age, adiposity, fasting hyperglycemia, and the PNPLA3 I148M variant also were associated with fibrosis. In patients without, but not in those with NASH, significant fibrosis was associated with steatosis grade and the PNPLA3 I148M variant. In patients without NASH, age, fasting hyperglycemia, ballooning, and inflammation were associated with fibrosis. In the validation cohort, 16 of 47 patients (34.0%) with clinically significant fibrosis did not have NASH at baseline. In patients with fibrosis without baseline NASH, worsening of fibrosis (based on later biopsies) was associated with fasting hyperglycemia and more severe steatosis (P = .016). CONCLUSIONS: In an analysis of biopsy specimens collected from patients with NAFLD at a single time point, one third of patients with significant fibrosis did not have NASH. We validated this finding in a separate cohort. In patients without NASH, fasting hyperglycemia, severe steatosis, mild inflammation or ballooning, and the PNPLA3 I148M variant identified those at risk of significant fibrosis.
引用
- Pelusi S, Cespiati A, Rametta R, et al. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Clin Gastroenterol Hepatol. 2019. PMID: 30708111. doi:10.1016/j.cgh.2019.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。